Abeona Therapeutics Inc.
ABEO
$4.78
$0.183.91%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -7.32% | -96.35% | |||
| Gross Profit | 7.32% | 94.41% | |||
| SG&A Expenses | 40.28% | -17.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.54% | -25.03% | |||
| Operating Income | -16.54% | 2.45% | |||
| Income Before Tax | -40.17% | 28.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -40.17% | 28.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -40.17% | 28.93% | |||
| EBIT | -16.54% | 2.45% | |||
| EBITDA | -17.62% | 1.74% | |||
| EPS Basic | -35.28% | 48.36% | |||
| Normalized Basic EPS | -34.90% | 51.46% | |||
| EPS Diluted | -35.28% | 48.36% | |||
| Normalized Diluted EPS | -34.90% | 51.46% | |||
| Average Basic Shares Outstanding | 3.62% | 37.63% | |||
| Average Diluted Shares Outstanding | 3.62% | 37.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
